Last reviewed · How we verify
Guideline directed heart failure therapy
At a glance
| Generic name | Guideline directed heart failure therapy |
|---|---|
| Sponsor | University of Edinburgh |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hyperkalemia
- Significant Hyperkalemia
- Hypovolemia
- Skin irritation
- Nausea
- Newly documented adverse reaction/intolerance to MRA
- Genital Mycotic Infection
- Abdominal pain
- Diarrhea
- Urinary Tract Infection
- Hypoglycemia
- Vomitting
Key clinical trials
- Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
- Telemedicine-Based Integrated Care for Heart Failure Prevention in Older Patients With Atrial Fibrillation (MIRACLE-AF III) (NA)
- Telemedicine-based Integrated Management of Atrial Fibrillation and Heart Failure in Older Patients in Village Clinics (NA)
- N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure (NA)
- Medication Withdrawal in Stable HF With Improved LVEF (PHASE2, PHASE3)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure
- Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: